A Review on Covid-19 Management and the Role of L-ascorbic Acid in the Co-V Medication Regimen

Since we all know that 2019–2021 were the most pandemic situation all over the world. The global COVID-19 pandemic has prompted significant research into effective management strategies and therapeutic interventions. Each and every age group was susceptible to the Co-V virus since it was new for everyone and the immune system couldn't recognize it and was unable to make that many potential antibiotics that could protect the people from being fought from it. Many of the people died all over the world, and there is no drug for the treatment of the disease. The mortality rate is very high throughout the country. Among the various potential treatments, vitamin C (L-ascorbic acid) has gained attention due to its immunomodulatory properties and potential to reduce the severity of viral infections. Vitamin C is an essential component that cannot be produced in the human body, but it is good against a wide range of upper respiratory infections, reducing hyper-inflammatory reactions and urge heal in infected areas. There are many findings, that prove that vitamin C has antioxidant, anti-inflammatory, anticoagulant, and immunomodulatory properties. The pneumonia patients are associated with low ascorbic acid levels and high oxidative stress. Pneumonia patients who consume vitamin C experience fewer harsh symptoms, and they are not much longer sick as patients not consuming vitamin C. In China and the United States, it has shown excellent results when a large proportion of intravenous L-Ascorbic acid is used for the management of Co-V.

The role of L-ascorbic acid in the management of COVID-19 as supplemental therapy was examined in this review. The survey focused on its biological mechanisms, such as enhancing immune function, acting as an antioxidant, and modulating inflammatory responses, all of which may encourage mitigating the pathophysiological effects of the virus.